Registration of Drug Product dossier application as per EU Guidelines
Abstract
Due to variations in the regulatory norms of registration dossier in different countries, there is a strong need for harmonization by ICH for approval of drugs. Generic drugs in EU are approved under the Marketing Authorization Application. Bioavailability and Bioequivalence study data is critical in the generic drug approval process. Moreover, there are several approaches to assess BA/BE, each regulatory authority has put forth its own regulations/guidances for conducting BA/BE studies. Medicinal products are highly regulated in the European Union (EU) and are subject to a separate, complicated system of approvals that governs how, when, where, and in what form such products will be allowed to be sold within the borders of EU. The present marketing authorization procedures applicable to European Economic Area included 27 EU member states and the three EEA European Free Trade Association states (Iceland, Liechtenstein and Norway). Marketing Authorization Application is applied based on National procedure, mutual recognition procedure, centralized and decentralized procedure. Hence procedure for Registration of Drug Products was discussed in detail in this current review.
Downloads
References
https://en.wikipedia.org/wiki/European_Medicines_Agency
2. EC Regulation No. 2309/93 [Internet]. European Medicines Agency; 2004 [cited 2018 May 17]. Available from:
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri =celex%3A32004R0726
3. Narla SK. Marketing Authorization of Human Medicinal Products to European Union/European Economic Area. Article-001, Directive 2003/63/EC, OJ L 159 June 2003. Int J Pharm Sci Rev Res. 2011; 10(1):46.
4. Notice to Applicants (NTA). Medicinal products for human use Volume 2B-CTD [Internet]. ICH; 2006 [cited 2018 May 09]. Available from:
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/b/update_200805/ctd_05-2008_en.pdf
5. European Medicines Agency [Internet]. EMA; 2018 [cited 2018 May 11]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000217.jsp&mid=
6. European Medicines AgencyCommittees Pharmaco-vigilance Risk Assessment Committee (PRAC) [Internet]. EMA; 2018 [cited 2018 May 18]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp
7. European Medicines Agency; [Internet] Committees ¬- Committee for Orphan Medicinal Products (COMP) [Internet]. 2018 [cited 2018 May 12]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000263.jsp
8. European Medicines Agency [Internet]. Committees¬- Committee on Herbal Medicinal Products (HMPC) [Internet]. 2018 [cited 2018 May 13]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000264.jsp
9. European Medicines Agency. Committees ¬ Committee for Advanced Therapies (CAT) [Internet]. EMEA; 2018 [cited 2018 May 14]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp&mid=WC0b01ac05800292a4
10. European Medicines Agency. Committees Pediatric Committee [Internet]. EMEA; 2018 [cited 2018 May 17]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000265.jsp&mid=WC0b01ac0580028e9d
11. European Medicines Agency. EU Member States National competent authorities (human) [Internet]. 2018 [cited 2018 May 18]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_000155.jsp&mid=WC0b01ac0580036d63
12. Johnston M and Goldstein M. European Union Development Cooperation Activities in Nicaragua. EU Blue Book; 2008.
13. Marketing Authorization in EU [Internet]. SGS’ Life Science article; 2006 [cited 2018 May 09]. Available from:
https://www.sgsgroup.fr/~/media/.../SGS-Clinical-Marketing-Authorization-EN-09.pdf
14. Notice to applicants and regulatory guidelines medicinal products for human use. Chapter 1 Marketing Authorisation [Internet]. EMEA; 2013. [cited 2018 May 08]. Available from:
https://ec.europa.eu/health/sites/health/files/files/.../vol.../vol2a_chap1rev6_201612.p...
15. Jawahar N et al. Procedures and applications for MAA. J. Pharm. Sci. & Res. [Internet]. 2015 [cited 2018 May 11]; 7(4): 219-25. Available from:
www.jpsr.pharmainfo.in/Documents/Volumes/vol7Issue04/jpsr07041508.pdf
16. Type of medicine [Internet]. Taylor wessing; 2018 [cited 2018 May 22]. Available from:
https://united-kingdom.taylorwessing.com/synapse/ regulatory _type.html
17. Legal Types of MAs in the EU/EEA. Article-001 [Internet]. 2011 [cited 2018 May 15]. Available from:
globalresearchonline.net/journalcontents/volume10issue1/Article-001.pdf
18. Notice to applicants and regulatory guidelines medicinal products for human use. Chapter 4 -Centralized Procedure [Internet]. EMEA; 2006 [cited 2018 May 17]. Available from:
https://ec.europa.eu/health/sites/health/files/files/.../vol.../vol2a_chap1_rev6_201612.p...
19. Notice to applicants and regulatory guidelines medicinal products for human use. Chapter 2. Mutual Recognition [Internet]. EMEA; 2007 [cited 2018 May 16]. Available from:
https://ec.europa.eu/health/sites/health/files/files/...2/vol2a_chap1_rev6_201612.pdf
20. National Marketing authorisation procedure [Internet]. [cited 2018 May 17]. Available from:
https://www.slideshare.net/clarityeye/marketing-authorization-in-the-eu
21. Decentralised Procedure [Internet]. Slide share; 2013 [cited 2018 May 14]. Available from:
https://www.slideshare.net/bdvfgbdhg/registration-procedure-of-drugs-in-european-union
22. Drug registration process in EU [Internet]. Slide share; 2013 [cited 2018 May 12]. Available from:
https://www.slideshare.net/gas25/us-and-eu-submission-comparative
23. Compilation of European Commission and Agency guidelines. General content [Internet]. 2018 [cited 2018 May 16]. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000043.jsp&mid=WC0b01ac05800240cb
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
